Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. India
  4. NSE India Stock Exchange
  5. Cipla Limited
  6. Summary
    CIPLA   INE059A01026

CIPLA LIMITED

(CIPLA)
  Report
Delayed Quote. Delayed NSE India Stock Exchange - 06/24 07:16:16 am
950.9 INR   -0.72%
06/23CIPLA  : Gets USFDA's Approval for Inflammatory Lung Disease Drug
MT
06/09Indian shares rise on financials boost as COVID-19 cases fall
RE
05/24CIPLA  : to Market Roche's COVID-19 Treatment Drug in India
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nse India Stock Exchange
06/18/2021 06/21/2021 06/22/2021 06/23/2021 06/24/2021 Date
960.9(c) 960.15(c) 955.85(c) 957.75(c) 950.9 Last
4 978 288 1 625 660 2 344 400 1 807 471 1 769 651 Volume
+1.05% -0.08% -0.45% +0.20% -0.72% Change
More quotes
Estimated financial data (e)
Sales 2021 196 B 2 639 M 2 639 M
Net income 2021 26 116 M 352 M 352 M
Net Debt 2021 1 438 M 19,4 M 19,4 M
P/E ratio 2021 29,8x
Yield 2021 0,41%
Sales 2022 211 B 2 852 M 2 852 M
Net income 2022 27 518 M 371 M 371 M
Net cash position 2022 19 735 M 266 M 266 M
P/E ratio 2022 28,0x
Yield 2022 0,51%
Capitalization 767 B 10 340 M 10 343 M
EV / Sales 2021 3,93x
EV / Sales 2022 3,53x
Nbr of Employees 25 845
Free-Float 61,4%
More Financials
Company
Cipla Limited is a holding company. The Company is a pharmaceutical company. The Company's strategic business units include Active Pharmaceutical Ingredients (APIs), Respiratory and Cipla Global Access. The Company's geographical segments include India, USA, South Africa and Rest of the World. The Company manufactures metered dose inhalers, dry powder inhalers, nasal sprays, nebulizers and a range of inhaled... 
Sector
Pharmaceuticals
Calendar
08/06Earnings Release
More about the company
Ratings of Cipla Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about CIPLA LIMITED
06/23CIPLA  : Gets USFDA's Approval for Inflammatory Lung Disease Drug
MT
06/09Indian shares rise on financials boost as COVID-19 cases fall
RE
05/24CIPLA  : to Market Roche's COVID-19 Treatment Drug in India
MT
05/20CIPLA  : Launches COVID-19 Test Kit 'ViraGen' in India
MT
05/18CIPLA  : Nomura Adjusts Cipla's Price Target to 1,051 Indian Rupees From 861 Ind..
MT
05/17CIPLA  : Consolidated Profit Jumps in Fiscal Q4; Shares Drop 3%
MT
05/10Indian shares settle up as record high commodity prices lift metal stocks
RE
05/10India COVID cases hold close to record highs as calls widen for national lock..
RE
05/09Eli Lilly signs deals to boost supply of COVID-19 treatment in India
RE
05/06Indian shares pare gains as coronavirus cases surge past 21 mln
RE
05/05CIPLA  : Roche Gets Emergency Use Authorization in India for COVID-19 Treatment ..
MT
05/04Indian shares tumble as domestic COVID-19 cases shoot past 20 million
RE
05/03CIPLA  : Associate Company Forms New Subsidiary
MT
05/03Glenmark, Alembic, Ipca Invest in ABCD Technologies; Stakes of Dr. Reddy's, O..
MT
04/29CIPLA  : Ties Up with MSD for COVID-19 Investigational Drug Molnupiravir
MT
More news
News in other languages on CIPLA LIMITED
04/27Merck ermöglicht indischen Generikaherstellern Zugang zu Covid-19-Kandidaten
02/23Farmacéuticas indias se vuelven locales para terminar con dependencia de Chin..
2020CIPLA  : L'Inde autorise une version générique de l'anti-COVID de Gilead
More news
Analyst Recommendations on CIPLA LIMITED
More recommendations
Chart CIPLA LIMITED
Duration : Period :
Cipla Limited Technical Analysis Chart | CIPLA | INE059A01026 | MarketScreener
Technical analysis trends CIPLA LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 31
Last Close Price 950,90 INR
Average target price 1 000,77 INR
Spread / Average Target 5,24%
EPS Revisions
Managers and Directors
NameTitle
Umang Vohra Chief Executive Officer, MD & Director
Raju Mistry President & Global Chief People Officer
Kedar Upadhye Global Chief Financial Officer
Yusuf Khwaja Hamied Non-Executive Chairman
Jaideep A. Gogtay Global Chief Medical Officer
Sector and Competitors